Clinical Trial Trends: Non-small Cell Lung Cancer (NSCLC)
There are 3,731 planned or ongoing NSCLC trials as of January 23, 2024
The article provides a comprehensive overview of the current landscape for non‑small‑cell lung cancer (NSCLC) clinical trials, detailing the number of planned and ongoing studies, their distribution across phases and countries, and illustrating Precision for Medicine’s extensive experience—particularly in early‑phase NSCLC research.
Accurate mapping of the NSCLC trial pipeline identifies research gaps, informs funding priorities, and highlights opportunities for accelerated therapeutic development and patient access to innovative treatments.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT